These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24940700)

  • 1. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
    Erb N; Harms DO; Janka-Schaub G
    Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
    Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
    Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase--an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line.
    Kalra S; Paul MK; Balaram H; Mukhopadhyay AK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):7-14. PubMed ID: 17081813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
    Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
    Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.
    Bostrom B; Erdmann G
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):80-6. PubMed ID: 8447563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L; Welch JC; Lilleyman JS
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
    Berkovitch M; Matsui D; Zipursky A; Blanchette VS; Verjee Z; Giesbrecht E; Saunders EF; Evans WE; Koren G
    Med Pediatr Oncol; 1996 Feb; 26(2):85-9. PubMed ID: 8531858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
    Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
    JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.
    Hanff LM; Mathot RA; Smeets O; Postma DJ; Ramnarain S; Vermes A; Pieters R; Zwaan CM
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):653-62. PubMed ID: 24800919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.